For the first quarter of FY2027, consolidated net sales were 587,612 thousand yen, operating loss 130,261 thousand yen, ordinary loss 106,092 thousand yen, and net loss attributable to owners of the parent 107,018 thousand yen. Compared with the same period of the previous year, sales were slightly down and profits turned to substantial losses. Segment results show the regenerative medicine-related business achieved black figures, while cosmetics, beauty & wellbeing, and sustainable businesses faced declines in revenue and expanded losses. Important matters regarding the going concern premise exist.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3840","jir_company_name":"Path Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/3840-20260813-01.pdf","jir_short_summary":"For the first quarter of FY2027, consolidated net sales were 587,612 thousand yen, operating loss 130,261 thousand yen, ordinary loss 106,092 thousand yen, and net loss attributable to owners of the parent 107,018 thousand yen. Compared with the same period of the previous year, sales were slightly down and profits turned to substantial losses. Segment results show the regenerative medicine-related business achieved black figures, while cosmetics, beauty & wellbeing, and sustainable businesses faced declines in revenue and expanded losses. Important matters regarding the going concern premise exist.","jir_summary":"### Overview of results\nConsolidated net sales for the quarter were 587,612 thousand yen, down year over year. Operating loss was 130,261 thousand yen, ordinary loss 106,092 thousand yen, and net loss attributable to owners of the parent 107,018 thousand yen. By segment, the regenerative medicine-related business posted substantial increases in both revenue and profit, while the cosmetics business, Beauty & Wellness, and sustainability businesses saw revenue declines and expanded losses. Ongoing reevaluation of the medium\u2011term plan and strengthening of the financial base are being pursued.\n\n### Outlook and financial measures\nWe are rebuilding the medium-term management plan to optimize the portfolio based on investment efficiency and market growth. We will push for fundamental restructuring of low\u2011profit businesses, high value-added strategies in cosmetics and beauty, new product development in regenerative medicine, and selectivity and concentration in the sustainability business. In terms of capital policy, we will consider flexible responses including use of external funds to strengthen the financial base and risk management.","jir_financial_highlights":"Net sales: 587,612 (YoY \u25b311,738 thousand yen)\nOperating loss: \u25b3130,261 (Compared with YoY \u25b3154,894, improvement)\nOrdinary loss: \u25b3106,092 (Compared with YoY \u25b3157,221, improvement)\nNet income attributable to owners of the parent: \u25b3107,018 (Compared with YoY \u25b3152,788, improvement)\nShareholders\u2019 equity ratio: 81.1% (Increased from 75.4% at year-end)","jir_category":"","jir_hashtags":"#PathCo.,Ltd., #Earnings, #MediumTermManagementPlan, #FinancialStability","jir_key_figures":"Net sales: 587,612 thousand yen (YoY \u25b311,738 thousand yen)\nOperating loss: \u25b3130,261 thousand yen\nNet loss attributable to owners of the parent: \u25b3107,018 thousand yen","jir_meta_title":"\u3010Path Co., Ltd.\u3011Q1 FY2027 Financial Summary | Net Sales 587,612 thousand yen, Net Loss","jir_meta_description":"Key points of Path Co., Ltd.'s Q1 FY2027 Financial Summary. Highlights on net sales and profits, segment trends, important matters regarding the going concern premise, and future policy and financial measures.","jir_og_title":"Path Co., Ltd. Q1 FY2027 Results Analysis | Net Sales 587,612 thousand yen, Net Loss","jir_og_description":"Summary of Path Co., Ltd.'s Q1 results. Regenerative medicine remains profitable, while some businesses face revenue decline and profit deterioration. Strategy and financial measures going forward.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60203,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103528","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n